3.1 CaOx crystals reduce the viability and induce apoptosis of HK-2 cells.
HK-2 cells were treated with a CaOx crystal suspension (0.1, 0.25, 0.5, 1.0, 2.0, and 4.0 mM) for 24 h and apoptosis was detected by flow cytometry. The percentage of cells undergoing apoptosis in response to 0, 0.1, 0.25, 0.5, 1.0, 2.0, and 4.0 mM CaOx treatment was 3.41 ± 0.78, 8.48 ± 0.32, 13.6 ± 0.57, 21.2 ± 0.85, 26.1 ± 0.76, 35.4 ± 0.62, and 45.4 ± 0.46, respectively(Fig. 1). The MTT assay showed that CaOx crystals decreased HK-2 cell viability in a concentration- as well as time-dependent manner(Fig. 2).
3.2 TFL protects HK-2 cells from damage induced by CaOx crystals
The percentages of cells undergoing apoptosis after 2 h pretreatment with TFL (0, 10, 25, 50, and 125 µg/ml) followed by treatment with a 2 mM CaOx crystal suspension for 24 h were 27.4 ± 5.00, 24.4 ± 2.64, 17.3 ± 2.34, 13.7 ± 1.92, and 12.3 ± 2.20, respectively(Fig. 3). Apoptosis significantly decreased after pretreatment with 25, 50, and 125 µg/mL TFL than the control group (P < 0.01), but there was no significant difference between the 50 and 125 µg/mL groups (P > 0.05). The MTT assay showed that TFL treatment mitigated the damage to HK-2 cells induced by CaOx crystals, while cell survival increased gradually with increasing concentrations of TFL(Fig. 4). The survival of cells pretreated with 50 and 125 µg/mL of TFL was significantly higher than that of the control group (P < 0.05 and P < 0.01, respectively), but there was no significant difference between these two groups (P > 0.05).
* P < 0.05, ** P < 0.01 vs. 0 mM oxalate group
* P < 0.05, ** P < 0.01 vs. 0 mM oxalate group
3.3 TFL reduces CaOx stone-induced OS in vitro and in vivo
SOD activity in CaOx crystal-treated HK-2 cells was significantly lower (P < 0.01) than that in normal control HK-2 cells, and the MDA content was higher (P < 0.05) (Fig. 6). This confirmed the presence of OS in CaOx crystal-treated HK-2 cells. After intervention with TFL, SOD activity was significantly increased (P < 0.01) and the MDA content was markedly decreased (P < 0.01) as compared to levels in CaOx crystal-treated HK-2 cells not exposed to TFL, indicating that TFL can reduce OS induced by CaOx crystals. In vivo experiments confirmed the in vitro results. As shown in Fig. 7, SOD activity in the kidney tissue of CaOx stone model rats was significantly lower (P < 0.01) and the MDA content was higher (P < 0.05) than those in the kidney tissue of control rats. After intervention with moderate and high TFL doses, SOD activity was significantly increased and the MDA content was decreased (P < 0.05), as compared with levels in model rats.
3.4 TFL increases the nuclear Nrf2 content and downstream antioxidant gene expression in CaOx crystal-induced HK-2 cells
Western blotting data showed that there was no significant difference in the expression of total Nrf2 protein between HK-2 cells treated with CaOx crystals and normal cells (P > 0.05) (Fig. 8B). However, Nrf2 expression in nuclear extracts, and HO-1 and NQO-1 expression, were upregulated in CaOx crystal-treated HK-2 cells (Fig. 8D, E, and F). After intervention with TFL, nuclear Nrf2, HO-1, and NQO-1 expression was further increased, indicating that TFL could activate the Nrf2/ARE pathway.
3.5 Nrf2/ARE pathway is downregulated in HK-2 cells after Nrf2 siRNA treatment
We first evaluated the Nrf2/ARE pathway by inactivating it with Nrf2 siRNA. After Nrf2 siRNA treatment, the Nrf2/ARE pathway was efficiently downregulated (P < 0.01) in HK-2 cells as compared with NC Nrf2 siRNA treatment (Fig. 9B, C, and D). Along with decreasing Nrf2 levels, Nrf2 siRNA markedly reduced the HO-1 and NQO-1 protein levels (P < 0.01) (Fig. 9E and F), indicating that we could effectively silence the expression of Nrf2 in cells and affect the expression of downstream genes by siRNA treatment. Importantly, Nrf2 siRNA treatment reversed the upregulated expression of nuclear Nrf2, HO-1, and NQO-1 induced by CaOx crystals in HK-2 cells (Fig. 8D, E, and F). The levels were even lower than those in the normal control group (p < 0.01). Furthermore, after Nrf2 siRNA treatment, TFL did not show any effect on the expression of nuclear Nrf2, HO-1, NQO-1, in CaOx crystal-treated HK-2 cells.
3.6 Nrf2/ARE pathway mediates the effect of TFL on OS
TFL treatment significantly increased SOD activity and significantly reduced the MDA content in HK-2 cells treated with CaOx crystals. TFL also increased nuclear Nrf2, and HO-1, and NQO-1 expression. However, Nrf2 siRNA treatment reversed the upregulated expression of nuclear Nrf2, HO-1, and NQO-1, induced by TFL in CaOx crystal-treated HK-2 cells (Fig. 4D, E, and F). As shown in Fig. 6, Nrf2 siRNA treatment also markedly decreased SOD activity (P < 0.01) and increased the MDA content (P < 0.01) in CaOx crystal-treated HK-2 cells exposed to TFL. These results were not different from the results in HK-2 cells treated with Nrf2 siRNA and CaOx alone (P > 0.05), indicating that there was no significant effect of TFL treatment on CaOx crystal-induced OS after Nrf2 siRNA treatment.
3.7 TFL inhibits the formation of renal calculi in a CaOx stone rat model
As shown in Table 1, CaOx stone model rats exhibited diminished body weight and a higher kidney weight/body weight ratio, which indicates kidney hypertrophy compared to normal rats. Hematoxylin/eosin staining showed broadly dilated kidney tubules and crystal deposition in the renal tubule lumen of CaOx stone model rats (Fig. 5); the crystallization score was 2.30 ± 0.26 and the renal tubule dilation score was 3 (Table 1). These scores were significantly higher than those in the normal control group, which suggests that the CaOx stone rat model was successfully established. Rats in the high-dose TFL treatment group showed a reduced kidney weight/body weight ratio, a low degree of crystal formation, and a lower degree of renal tubule dilation than did CaOx stone model rats (Table 1). However, treatment with low- and medium-dose TFL did not show a significant effect.
Table 1
Effect of TFL on the renal tissue of CaOx stone model rats
Parameters
|
NC
|
M
|
LT
|
MT
|
HT
|
BW loss (g)
|
7.00 ± 13.65
|
45.5 ± 24.2**
|
32.0 ± 19.2**
|
31.5 ± 9.8**
|
28.8 ± 20.8**#
|
KW (g)
|
1.89 ± 0.29
|
2.64 ± 0.86**
|
2.65 ± 0.69**
|
2.58 ± 0.70*
|
2.15 ± 0.28
|
KW/BW (%)
|
0.69 ± 0.09
|
1.07 ± 0.40**
|
1.09 ± 0.26**
|
0.95 ± 0.21*
|
0.84 ± 0.10#
|
SCD
|
0.50 ± 0.22
|
2.30 ± 0.26**
|
2.00 ± 0.26**
|
2.00 ± 0.21**
|
1.50 ± 0.22**#
|
SRTDD
|
0 (0-)
|
3 (1–4)**
|
3 (1–4)**
|
3 (1–4)**
|
2 (1–3)**#
|
SRTDD data are presented as medians (range). All other data are presented as means ± SEM.
KW, kidney weight; BW, body weight; SCD, score of crystallization degree; SRTDD, score of renal tubule dilatation degree.
* P < 0.05, ** P < 0.01 vs. Group A.
# P < 0.05, ## P < 0.01 vs. Group B.
* P < 0.05, ** P < 0.01 vs. NC group
# P < 0.05, ## P < 0.01 vs. M group
Δ P < 0.05, ΔΔ P < 0.01 vs. M + TFL group
* P < 0.05, ** P < 0.01 vs. NC group.
# P < 0.05, ## P < 0.01 vs. M group.
* P < 0.05, ** P < 0.01 vs. NC group,
# P < 0.05, ## P < 0.01 vs. M group
(A) Western blot analyses showing the protein expression levels of Nrf2, HO-1, and NQO-1 after transfecting Nrf2 siRNA into HK-2 cells. (B) Relative density of total Nrf2 expression with β-actin as the loading control. (C) Relative density of intracellular Nrf2. (D) Relative density of nuclear Nrf2. (E) Relative density of HO-1. (F) Relative density of NQO-1. Values are presented as means ± SEM.
* P < 0.05, ** P < 0.01.